Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Bosentan

Bosentan Am J Cardiovasc Drugs 2002; 2 (5): 343 GUEST COMMENTARIES 1175-3277/02/0005-0343/$25.00/0 © Adis International Limited. All rights reserved. appears to be dose-related and reversible upon dose reduction or discontinuation, but requires monthly monitoring of liver func- A Viewpoint by Lewis J. Rubin tion. Based on its efficacy and safety profile, coupled with its oral University of California, San Diego School of Medicine, La Jolla, California, USA route of administration, bosentan is considered by many experts as the initial treatment of choice for patients with PAH who fall Endothelin (ET) is a potent pulmonary vasoconstrictor and into WHO Functional Class III or early IV. mitogen that is overexpressed by the endothelium of hypertensive Although bosentan is a major advance in the treatment of pulmonary arteries. Additionally, circulating levels of ET are el- PAH, the following issues remain to be addressed: (i) what are evated in patients with pulmonary artery hypertension (PAH), the long-term effects of bosentan in PAH? Since the trials pub- and the magnitude of the increase correlates with prognosis. lished thus far have reported on patients treated only 3 to 6 These observations provided a strong rationale for blockade of months, long-term experience with therapy is needed; (ii) http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png American Journal of Cardiovascular Drugs Springer Journals

Bosentan

Rubin, Lewis
American Journal of Cardiovascular Drugs , Volume 2 (5) – Aug 20, 2012
Download PDF
1 page

Bosentan

Abstract

Am J Cardiovasc Drugs 2002; 2 (5): 343 GUEST COMMENTARIES 1175-3277/02/0005-0343/$25.00/0 © Adis International Limited. All rights reserved. appears to be dose-related and reversible upon dose reduction or discontinuation, but requires monthly monitoring of liver func- A Viewpoint by Lewis J. Rubin tion. Based on its efficacy and safety profile, coupled with its oral University of California, San Diego School of Medicine, La Jolla, California, USA route of administration, bosentan is...
Loading next page...
 
/lp/springer-journals/bosentan-DLnMqWEp0R

References (0)

References for this paper are not available at this time. We will be adding them shortly, thank you for your patience.

Publisher
Springer Journals
Copyright
Copyright © 2002 by Adis International Limited
Subject
Medicine & Public Health; Cardiology; Pharmacotherapy; Pharmacology/Toxicology
ISSN
1175-3277
eISSN
1179-187X
DOI
10.2165/00129784-200202050-00007
Publisher site
See Article on Publisher Site

Abstract

Am J Cardiovasc Drugs 2002; 2 (5): 343 GUEST COMMENTARIES 1175-3277/02/0005-0343/$25.00/0 © Adis International Limited. All rights reserved. appears to be dose-related and reversible upon dose reduction or discontinuation, but requires monthly monitoring of liver func- A Viewpoint by Lewis J. Rubin tion. Based on its efficacy and safety profile, coupled with its oral University of California, San Diego School of Medicine, La Jolla, California, USA route of administration, bosentan is considered by many experts as the initial treatment of choice for patients with PAH who fall Endothelin (ET) is a potent pulmonary vasoconstrictor and into WHO Functional Class III or early IV. mitogen that is overexpressed by the endothelium of hypertensive Although bosentan is a major advance in the treatment of pulmonary arteries. Additionally, circulating levels of ET are el- PAH, the following issues remain to be addressed: (i) what are evated in patients with pulmonary artery hypertension (PAH), the long-term effects of bosentan in PAH? Since the trials pub- and the magnitude of the increase correlates with prognosis. lished thus far have reported on patients treated only 3 to 6 These observations provided a strong rationale for blockade of months, long-term experience with therapy is needed; (ii)

Journal

American Journal of Cardiovascular Drugs – Springer Journals

Published: Aug 20, 2012

There are no references for this article.